Main Logo
Logo

Society for Pediatric Radiology – Poster Archive

  320
  0
  0
 
 


Final ID: Paper #: 034

Development of Diagnostic Imaging Criteria for Clinical Trials in Pediatric Patients with Pulmonary Fibrosis

Purpose or Case Report: Children’s interstitial lung diseases (chILD) comprise a large spectrum of rare diffuse lung disorders, with a subset of patients developing chronic fibrosing lung disease. While imaging criteria for lung fibrosis are established for adults and correlate with prognosis and outcome, there are limited data on imaging for diagnosis, prognosis, and outcomes in children with fibrotic lung disease. To fill this gap, a group of ILD specialists aimed to define the imaging features for diagnosis of lung fibrosis for a forthcoming randomized trial of nintedanib versus placebo in pediatric patients with fibrosing ILD (1199-0337; NCT04093024).
Methods & Materials: Imaging criteria for diagnosis of adult pulmonary fibrosis were reviewed by an international panel of radiologists and pulmonologists with experience in ILD and clinical trial application. High-resolution computed tomography (HRCT) scans from chILD cases with suspected fibrosis were reviewed and the adult imaging criteria adapted based on the characteristics observed. The resulting imaging criteria for lung fibrosis in chILD were agreed by expert consensus. In a case study, data driven texture analysis software (Humphries, Radiol 2017) was used to quantify the imaging criteria and changes over time on four longitudinal chest CT scans in a child with a genetic mutation of SFTPC.
Results: Study eligibility will be determined based on documented evidence of fibrotic lung disease by centrally confirmed HRCT. To qualify, patients need two longitudinal CT scans with at least two of: reticular abnormality, traction bronchiectasis, honeycombing, architectural distortion, or cystic abnormality. For patients with previous findings of fibrosis on lung biopsy, a single chest CT with either reticular abnormality, honeycombing, traction bronchiectasis, or architectural distortion will be sufficient. Ground glass opacity can be present but does not qualify as one of the fibrotic criteria. Findings from the case-study based on these imaging criteria appeared to show increased fibrosis over time.
Conclusions: Criteria for diagnosis of chronic fibrosing ILD in pediatric patients have been defined for evaluation in clinical trials. Case-study evaluation of changes over time suggests these criteria may also be useful to evaluate treatment response. Qualitative and quantitative methods will be used to assess fibrotic changes on chest CT in a sub-study of the planned clinical trial of nintedanib in children with lung fibrosis.
  • Deboer, Emily  ( University of Colorado Anschutz Medical Campus and Children’s Hospital Colorado , Aurora , Colorado , United States )
  • Deterding, Robin  ( University of Colorado Anschutz Medical Campus and Children’s Hospital Colorado , Aurora , Colorado , United States )
  • Lynch, David  ( National Jewish Health , Denver , Colorado , United States )
  • Humphries, Stephen  ( National Jewish Health , Denver , Colorado , United States )
  • Jacob, Joseph  ( University College London , London , United Kingdom )
  • Devaraj, Anand  ( Royal Brompton Hospital , London , United Kingdom )
  • Ley-zaporozhan, Julia  ( Pediatric Radiology, Ludwig-Maximilian University , Munich , Germany )
  • Griese, Matthias  ( Hauner Children’s Hospital, Ludwig-Maximilian University , Munich , Germany )
  • Schiwek, Marilisa  ( Boehringer Ingelheim International GmbH , Ingelheim am Rhein , Germany )
  • Stowasser, Susanne  ( Boehringer Ingelheim International GmbH , Ingelheim am Rhein , Germany )
  • Clerisme-beaty, Emmanuelle  ( Boehringer Ingelheim International GmbH , Ingelheim am Rhein , Germany )
Session Info:

Scientific Session II-A: Thoracic

Thoracic Imaging

SPR Scientific Papers

More abstracts on this topic:
Preview
Paper____034.pdf
You have to be authorized to contact abstract author. Please, Login or Signup.

Please note that this is a separate login, not connected with your credentials used for the SPR main website.

Not Available

Comments

We encourage you to join the discussion by posting your comments and questions below.

Presenters will be notified of your post so that they can respond as appropriate.

This discussion platform is provided to foster engagement, and stimulate conversation and knowledge sharing.

Please click here to review the full terms and conditions for engaging in the discussion, including refraining from product promotion and non-constructive feedback.

 

You have to be authorized to post a comment. Please, Login or Signup.

Please note that this is a separate login, not connected with your credentials used for the SPR main website.


   Rate this abstract  (Maximum characters: 500)